Ready-to-Assay LPA2 Lysophospholipid Receptor Frozen Cells

Millipore′s Ready-to-Assay GPCR frozen cells are designed for simple, rapid calcium assays with no requirement for intensive cell culturing. Millipore has optimized the freezing conditions to provide cells with high viability and functionality post-thaw. The user simply thaws the cells and resuspends them in media, dispenses cell suspension into assay plates and, following over night recovery, assays for calcium response.

Lysophosphatidic acid (LPA) is a lysophospholipid produced by activated platelets that inhibits adenylate cyclase and stimulates DNA synthesis, changes in cell morphology, and increases in intracellular calcium in a variety of cultured mammalian cells. A family of three GPCRs, LPA₁, LPA₂, and LPA₃, mediates the biological effects of LPA (Contos et al., 2000). LPA₂ is widely expressed, with particularly notable expression in helper T Cells (Huang et al.) LPA₂ upregulation has been demonstrated in multiple cancer cells, including colon and ovarian cancer (Yun et al.). LPA₂ couples to multiple signaling cascades through Gq Gi/o and G12/13, mediating inhibition of adenyl cyclase, inositol phosphate turnover, calcium flux and cell migration Millipore′s cloned human LPA₂ expressing cell line is made in the Chem-1 host, which supports high levels of recombinant LPA₂ expression on the cell surface and contains high levels of the promiscuous G protein Gα15 to couple the receptor to the calcium signaling pathway. Thus, the cell line is an ideal tool for screening for agonists, antagonists and modulators at LPA₂.

Human LPA2 Lysophospholipid GPCR Frozen Cells for calcium flux FLIPR Assays.

Pack contains 2 vials of mycoplasma-free cells, 1 ml per vial.
Fifty (50) mL of Media Component.

This product contains genetically modified organisms (GMO).
Within the EU GMOs are regulated by Directives 2001/18/EC and 2009/41/EC of the European Parliament and of the Council and their national implementation in the member States respectively.